PrEP (pre-exposure prophylaxis) is a new HIV prevention intervention. PrEP Watch is a clearinghouse for PrEP data, additional research, cost, access and advocacy efforts across the globe.
Countries are at varying stages of introducing daily oral PrEP using TDF/FTC, which is now recommended by WHO as an option for people at substantial risk of HIV. Some countries have national programs; others have smaller-scale programs; others aren’t offering PrEP at all. In this map, yellow countries have some form of PrEP programming; blue countries do not. Check back for regular updates!
This framework outlines the steps in this process for PrEP programs to have an impact and provides links to specific tools and resources for the following steps.
July 6, 2017
The surprise approval of generic Truvada by the US FDA left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.
June 21, 2017
Wits RHI has released a new video, Get PrEPared: What African women need to know, offering practical and easy-to-understand information for young African women interested in using PrEP as part of an overall HIV prevention package.
June 15, 2017
Experts cited complicated factors, like patient and doctor awareness and the unique way the US HIV medication market functions, as barriers to access.
June 14, 2017
The Vietnam Administration for AIDS Control launched an oral PrEP prescription service this past March. This pilot program will run until September 2018, when it will be re-evaluated by the Ministry of Health.
June 9, 2017
The US Food and Drug Administration has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine).
June 5, 2017
In the last two weeks, several countries have announced that they will soon launch pre-exposure prophylaxis (PrEP) programs.